TY - JOUR
T1 - Asymptomatic atrial fibrillation
T2 - Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study
AU - Flaker, Greg C.
AU - Belew, Kathy
AU - Beckman, Karen
AU - Vidaillet, Humberto
AU - Kron, Jack
AU - Safford, Robert
AU - Mickel, Mary
AU - Barrell, Patrick
N1 - Funding Information:
Grant support for this study was provided by the National Heart, Lung, and Blood Institute under contract no. N01-HC-55139.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005/4
Y1 - 2005/4
N2 - Background: Atrial fibrillation (AF) may occur without symptoms. Little is known about demographic features and prognostic information in patients with asymptomatic AF. Methods: In the AFFIRM study, 4060 patients were randomized to either rhythm or rate control. At baseline, patients were identified as asymptomatic if they answered "no" to a 15-item questionnaire related to cardiac symptoms during AF in the 6 months before study entry. Results: There were 481 (12%) asymptomatic patients at baseline. Compared with symptomatic patients, asymptomatic patients were more often men and had a lower incidence of coronary artery disease and congestive heart failure, but had more cerebrovascular events. Asymptomatic patients had a longer duration of AF, a lower maximum heart rate, and better left ventricular function. They received fewer cardiac medications and fewer therapies to maintain sinus rhythm. At 5 years, there was a trend for better survival in asymptomatic patients (81% vs 77%, P =. 058), and they were more likely to be free from disabling stroke or anoxic encephalopathy, major bleeding, and cardiac arrest (79% vs 67%, P =. 024). However, mortality and major events were similar after correction for baseline differences. Conclusions: Patients with asymptomatic AF have less serious heart disease but more cerebrovascular disease. Asymptomatic patients receive different therapies than symptomatic patients. However, the absence of symptoms and the differences in treatment does not confer a more favorable prognosis when differences in baseline clinical parameters are considered. Anticoagulation should be considered in these patients.
AB - Background: Atrial fibrillation (AF) may occur without symptoms. Little is known about demographic features and prognostic information in patients with asymptomatic AF. Methods: In the AFFIRM study, 4060 patients were randomized to either rhythm or rate control. At baseline, patients were identified as asymptomatic if they answered "no" to a 15-item questionnaire related to cardiac symptoms during AF in the 6 months before study entry. Results: There were 481 (12%) asymptomatic patients at baseline. Compared with symptomatic patients, asymptomatic patients were more often men and had a lower incidence of coronary artery disease and congestive heart failure, but had more cerebrovascular events. Asymptomatic patients had a longer duration of AF, a lower maximum heart rate, and better left ventricular function. They received fewer cardiac medications and fewer therapies to maintain sinus rhythm. At 5 years, there was a trend for better survival in asymptomatic patients (81% vs 77%, P =. 058), and they were more likely to be free from disabling stroke or anoxic encephalopathy, major bleeding, and cardiac arrest (79% vs 67%, P =. 024). However, mortality and major events were similar after correction for baseline differences. Conclusions: Patients with asymptomatic AF have less serious heart disease but more cerebrovascular disease. Asymptomatic patients receive different therapies than symptomatic patients. However, the absence of symptoms and the differences in treatment does not confer a more favorable prognosis when differences in baseline clinical parameters are considered. Anticoagulation should be considered in these patients.
UR - http://www.scopus.com/inward/record.url?scp=17044425618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17044425618&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2004.06.032
DO - 10.1016/j.ahj.2004.06.032
M3 - Article
C2 - 15990749
AN - SCOPUS:17044425618
SN - 0002-8703
VL - 149
SP - 657
EP - 663
JO - American Heart Journal
JF - American Heart Journal
IS - 4
ER -